This Thursday marks the start of the "soul negotiation" for medical insurance. Which companies are likely to be selected?
According to the National Medical Insurance Administration, a press conference will be held at 10 a.m. on November 28 at the National Medical Insurance Administration to announce the adjustments to the national medical insurance pharmaceutical catalog for 2024 and answer questions from reporters. This means that the results of the national negotiation for medical insurance centralized purchasing in 2024 will be announced this Thursday.
Key stock indices in Hong Kong, major adjustments! 570 billion funds, embracing "change"!
Hang Seng Index latest adjustment! Today, Hang Seng Indexes Company Limited announced that Kuaishou Technology, new oriental education technology group will be included in the Hang Seng Index, while New World Development Company will be removed. The number of constituent stocks in the Hang Seng Index will increase from 82 to 83; China people's property insurance co., ltd. will be included in the Hang Seng H-Share Index ETF, while Longfor group holdings limited will be removed. The number of constituent stocks in the Hang Seng H-Share Index ETF will remain at 50; Midea Group Co., Ltd will be included in the Hang Seng Tech Index, while Weibo Co., Ltd. will be removed. The number of constituent stocks in the Hang Seng Tech Index will remain at 40. Hang Seng Indexes Company Limited stated that all changes will take effect in 2024.
The Import Expo focuses on the "pioneering and trial" policy, Hainan Lecheng, and the south china greater bay area concept become important platforms for innovative drugs and medical devices.
Thanks to the "policy green light" and innovative models, Hainan Lecheng and the South China Greater Bay Area concept are becoming important platforms to promote highly coordinated access to global medical resources, attracting top pharmaceutical companies globally and high-quality medical institutions domestically and internationally.
Zheshang: Innovative drugs, blood products and other fields may benefit from the slow recovery on the demand side.
Zheshang released research reports stating that the transition of pharmaceutical new and old kinetic energy will continue in the next stage, with innovative drugs, supply cleaning or better framework in areas such as innovative drug supporting industry chain, large infusion, anesthetic drugs, blood products, pharmaceutical circulation, traditional chinese medicine OTC, benefiting from the slow recovery on the demand side, potentially with better growth prospects.
Express News | Shanghai: Increase support for the overseas listing of innovative drug and medical device products, encourage enterprises to carry out overseas investment and mergers and acquisitions.
Express News | Shanghai Municipal People's Government Office issued the Action Plan for Enhancing the International Competitiveness of Biomedical Enterprises in Shanghai (2024-2027), targeting overseas markets, strengthening the research and development of innovative pr